Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

V. Abkevich, K. M. Timms, B. T. Hennessy, J. Potter, M. S. Carey, L. A. Meyer, K. Smith-Mccune, R. Broaddus, K. H. Lu, J. Chen, T. V. Tran, D. Williams, D. Iliev, S. Jammulapati, L. M. Fitzgerald, T. Krivak, J. A. Deloia, A. Gutin, Gordon Mills, J. S. Lanchbury

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

Background:Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).Methods:Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were performed on 57 cancer cell lines.Results:Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or BRCA2 (P10 11). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data sets (P10 5 and 10 29), and identified breast and pancreatic cell lines with BRCA defects.Conclusion:The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.

Original languageEnglish (US)
Pages (from-to)1776-1782
Number of pages7
JournalBritish Journal of Cancer
Volume107
Issue number10
DOIs
StatePublished - Nov 6 2012
Externally publishedYes

Fingerprint

Recombinational DNA Repair
Loss of Heterozygosity
Homologous Recombination
Ovarian Neoplasms
Neoplasms
Breast
Cell Line
Double-Stranded DNA Breaks
Platinum
Ovarian epithelial cancer
Datasets

Keywords

  • DNA double-strand break repair
  • Homologous recombination deficiency
  • Loss of heterozygosity
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., ... Lanchbury, J. S. (2012). Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. British Journal of Cancer, 107(10), 1776-1782. https://doi.org/10.1038/bjc.2012.451

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. / Abkevich, V.; Timms, K. M.; Hennessy, B. T.; Potter, J.; Carey, M. S.; Meyer, L. A.; Smith-Mccune, K.; Broaddus, R.; Lu, K. H.; Chen, J.; Tran, T. V.; Williams, D.; Iliev, D.; Jammulapati, S.; Fitzgerald, L. M.; Krivak, T.; Deloia, J. A.; Gutin, A.; Mills, Gordon; Lanchbury, J. S.

In: British Journal of Cancer, Vol. 107, No. 10, 06.11.2012, p. 1776-1782.

Research output: Contribution to journalArticle

Abkevich, V, Timms, KM, Hennessy, BT, Potter, J, Carey, MS, Meyer, LA, Smith-Mccune, K, Broaddus, R, Lu, KH, Chen, J, Tran, TV, Williams, D, Iliev, D, Jammulapati, S, Fitzgerald, LM, Krivak, T, Deloia, JA, Gutin, A, Mills, G & Lanchbury, JS 2012, 'Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer', British Journal of Cancer, vol. 107, no. 10, pp. 1776-1782. https://doi.org/10.1038/bjc.2012.451
Abkevich, V. ; Timms, K. M. ; Hennessy, B. T. ; Potter, J. ; Carey, M. S. ; Meyer, L. A. ; Smith-Mccune, K. ; Broaddus, R. ; Lu, K. H. ; Chen, J. ; Tran, T. V. ; Williams, D. ; Iliev, D. ; Jammulapati, S. ; Fitzgerald, L. M. ; Krivak, T. ; Deloia, J. A. ; Gutin, A. ; Mills, Gordon ; Lanchbury, J. S. / Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. In: British Journal of Cancer. 2012 ; Vol. 107, No. 10. pp. 1776-1782.
@article{ad2994b754d84a94a9bd37ffbf233a72,
title = "Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer",
abstract = "Background:Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).Methods:Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were performed on 57 cancer cell lines.Results:Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or BRCA2 (P10 11). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data sets (P10 5 and 10 29), and identified breast and pancreatic cell lines with BRCA defects.Conclusion:The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.",
keywords = "DNA double-strand break repair, Homologous recombination deficiency, Loss of heterozygosity, Ovarian cancer",
author = "V. Abkevich and Timms, {K. M.} and Hennessy, {B. T.} and J. Potter and Carey, {M. S.} and Meyer, {L. A.} and K. Smith-Mccune and R. Broaddus and Lu, {K. H.} and J. Chen and Tran, {T. V.} and D. Williams and D. Iliev and S. Jammulapati and Fitzgerald, {L. M.} and T. Krivak and Deloia, {J. A.} and A. Gutin and Gordon Mills and Lanchbury, {J. S.}",
year = "2012",
month = "11",
day = "6",
doi = "10.1038/bjc.2012.451",
language = "English (US)",
volume = "107",
pages = "1776--1782",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

AU - Abkevich, V.

AU - Timms, K. M.

AU - Hennessy, B. T.

AU - Potter, J.

AU - Carey, M. S.

AU - Meyer, L. A.

AU - Smith-Mccune, K.

AU - Broaddus, R.

AU - Lu, K. H.

AU - Chen, J.

AU - Tran, T. V.

AU - Williams, D.

AU - Iliev, D.

AU - Jammulapati, S.

AU - Fitzgerald, L. M.

AU - Krivak, T.

AU - Deloia, J. A.

AU - Gutin, A.

AU - Mills, Gordon

AU - Lanchbury, J. S.

PY - 2012/11/6

Y1 - 2012/11/6

N2 - Background:Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).Methods:Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were performed on 57 cancer cell lines.Results:Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or BRCA2 (P10 11). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data sets (P10 5 and 10 29), and identified breast and pancreatic cell lines with BRCA defects.Conclusion:The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.

AB - Background:Defects in BRCA1, BRCA2, and other members of the homologous recombination pathway have potential therapeutic relevance when used to support agents that introduce or exploit double-stranded DNA breaks. This study examines the association between homologous recombination defects and genomic patterns of loss of heterozygosity (LOH).Methods:Ovarian tumours from two independent data sets were characterised for defects in BRCA1, BRCA2, and RAD51C, and LOH profiles were generated. Publically available data were downloaded for a third independent data set. The same analyses were performed on 57 cancer cell lines.Results:Loss of heterozygosity regions of intermediate size were observed more frequently in tumours with defective BRCA1 or BRCA2 (P10 11). The homologous recombination deficiency (HRD) score was defined as the number of these regions observed in a tumour sample. The association between HRD score and BRCA deficiency was validated in two independent ovarian cancer data sets (P10 5 and 10 29), and identified breast and pancreatic cell lines with BRCA defects.Conclusion:The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.

KW - DNA double-strand break repair

KW - Homologous recombination deficiency

KW - Loss of heterozygosity

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84869079205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869079205&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.451

DO - 10.1038/bjc.2012.451

M3 - Article

C2 - 23047548

AN - SCOPUS:84869079205

VL - 107

SP - 1776

EP - 1782

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -